Filing Flows › Procept BioRobotics (PRCT) › Q2 2026 › vs Q2 2025
Procept BioRobotics (PRCT) Q2 2026 vs Q2 2025 (year over year)
Procept BioRobotics's revenue rose $15.3M (+19%) from $79.2M in Q2 2025 to $94.5M in Q2 2026.
Procept BioRobotics, Q2 2026: revenue $94.5M (+19% year over year), operating margin -29.0%, net loss $26.9M, operating cash flow −$19.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $94.5M | $79.2M | $15.3M | +19% |
| Other income, net | $623K | $2.7M | −$2.1M | -77% |
| Net loss | $26.9M | $19.6M | $7.3M | +37% |
| Costs & expenses | $122M | $102M | $20.5M | +20% |
| Operating costs | $122M | $101M | $20.5M | +20% |
| Income tax | $94K | $136K | −$42K | -31% |
| Cost of revenue | $32.1M | $27.4M | $4.7M | +17% |
| Research & development | $20.1M | $17.6M | $2.5M | +14% |
| SG&A | $69.7M | $56.3M | $13.4M | +24% |
| Operating cash sources | $35.8M | $28.8M | $7.0M | +24% |
| Depreciation & amortization | $2.0M | $1.6M | $401K | +25% |
| Share-based compensation | $14.5M | $12.2M | $2.4M | +19% |
| Cash used in operations | $19.3M | $15.0M | $4.2M | +28% |
| Net loss absorbed | $26.9M | $19.6M | $7.3M | +37% |
| Working capital & other | $8.9M | $9.2M | −$303K | -3% |
Questions
How much did Procept BioRobotics's revenue grow year over year in Q2 2026?
Procept BioRobotics's revenue rose $15.3M (+19%) from $79.2M in Q2 2025 to $94.5M in Q2 2026.